Therapies for Restless Legs in Parkinson’s Disease
Purpose of review
The aim of this article was to review the options and particularities of the treatment of restless legs syndrome (RLS) in Parkinson’s disease (PD).
RLS is more frequent in PD than in the general population. Even if these two disorders share some specificity (dopa-sensitivity), they also differ in many features (iron load, genetic profile, dopaminergic cell count), resulting in different adaptations of the treatment. Only one study has specifically explored and demonstrated the efficacy of a treatment (rotigotine) in RLS with PD, constraining us to treat RLS with PD by analogy as idiopathic RLS in the other cases. However, arrangements linked to the peculiar population and pathology of PD are required.
The treatment of RLS in PD consists in adaptation of dopaminergic treatment and introduction of alpha-2-delta ligands and, in refractory cases, of opioids or deep brain stimulation. Iron deficiency should probably not be compensated.
KeywordsRestless legs syndrome Periodic limb movements Parkinson’s disease Dopamine agonists Alpha-2-delta ligands Opioids Iron Deep brain stimulation
Compliance with Ethical Standards
Conflict of Interest
The author declares that she has no competing interests.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
References and Recommended Reading
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 1.Allen RP, Picchietti DL, Garcia-Borreguero D, Ondo WG, Walters AS, Winkelman JW, et al. Restless legs syndrome/Willis-Ekbom disease diagnostic criteria: Updated International Restless Legs Syndrome Study Group (IRLSSG) consensus criteria - history, rationale, description, and significance. Sleep Med. 2014;15:860–73.PubMedCrossRefGoogle Scholar
- 23.Loddo G, Calandra-Buonaura G, Sambati L, Giannini G, Cecere A, Cortelli P, et al. The treatment of sleep disorders in Parkinson’s disease: from research to clinical practice. Front Neurol. 2017;16:42.Google Scholar
- 24.Garcia-Borreguero D, Silber M, Winkelman JW, Hogl B, Bainbridge J, Buchfuhrer M. Guidelines for the first-line treatment of restless legs syndrome/Willis-Ekbom disease, prevention and treatment of dopaminergic augmentation: a combined task force of the IRLSSG, EURLSSG, and the RLS-foundation. Sleep Med. 2016;21:1–11.PubMedCrossRefGoogle Scholar
- 26.•• Winkelmann J, Allen RP, Högl B, Inoue Y, Oertel W, Salminen AV, et al. Treatment of restless legs syndrome: evidence-based review and implications for clinical practice (revised 2017). Mov Disord. 2018;33:1077–91. The newest evidence-based review on the treatment of idiopathic RLS.PubMedCrossRefGoogle Scholar
- 27.Perez-Perez J, Pascual-Sedano B, Campolongo A, Kulisevsky J. Duodopa for the treatment of severe restless legs syndrome. Mov Disord. 2016;31:S304Poster953.Google Scholar
- 28.Pagonabarraga J, Piñol G, Cardozo A, Sanz P, Puente V, Otermín P, et al. Transdermal rotigotine improves sleep fragmentation in parkinson’s disease: results of the multicenter, prospective SLEEP-FRAM study. Parkinsons Dis. 2015;2015:1315–8.Google Scholar
- 32.••Trenkwalder C, Kies B, Rudzinska M, Fine J, Nikl J, Honczarenko K, et al. Rotigotine effects on early morning motor function and sleep in Parkinson’s disease: a double-blind, randomized, placebo-controlled study (RECOVER). Mov Disord. 2011;26:90–9 The only randomized double blind study on the efficacy of a treatment in RLS with PD.PubMedCrossRefGoogle Scholar
- 37.Jost WH, Buhmann C. The challenge of pain in the pharmacological management of Parkinson’s disease. Expert Opin Pharmacother. 2019;10:1–8.Google Scholar
- 39.Garcia-Borreguero D, Larrosa O, De la Llave Y, Verger K, Masramon X, Hernandez G. Treatment of restless legs syndrome with gabapentin: a double-blind, cross-over study. Neurology. 2002;48:82–6.Google Scholar
- 47.Lal R, Ellenbogen A, Chen D, Zomorodi K, Atluri H, Luo W, et al. A randomized, double-blind, placebo-controlled, dose-response study to assess the pharmacokinetics, efficacy, and safety of gabapentin enacarbil in subjects with restless legs syndrome. Clin Neuropharmacol. 2012;35:165–73.PubMedCrossRefGoogle Scholar
- 48.Lee D, Ziman R, Perkins A, Poceta J, Walters A, Barrett R. A randomized, double-blind, placebo-controlled study to assess the efficacy and tolerability of gabapentin enacarbil in subjects with restless legs syndrome. J Clin Sleep Med. 2011;7:282–92.Google Scholar
- 55.Trenkwalder C, Beneš H, Grote L, García-Borreguero D, Högl B, Hopp M, et al. Prolonged release oxycodone-naloxone for treatment of severe restless legs syndrome after failure of previous treatment: a double-blind, randomised, placebo-controlled trial with an open-label extension. Lancet Neurol. 2013;12:1141–50.PubMedCrossRefGoogle Scholar
- 56.Trenkwalder C, Chaudhuri KR, Martinez-Martin P, Rascol O, Ehret R, Vališ M, et al. Prolonged-release oxycodone-naloxone for treatment of severe pain in patients with Parkinson’s disease (PANDA): a double-blind, randomised, placebo-controlled trial. Lancet Neurol. 2015;14:1161–70.PubMedCrossRefGoogle Scholar
- 66.Klepitskaya O, Liu Y, Tsai J. Deep brain stimulation (DBS) of the subthalamic nucleus (STN) improves restless leg syndrome (RLS) in patients with Parkinson disease (PD). Mov Disord. 2017;91:e1013–21.Google Scholar
- 68.•Marques A, Fantini ML, Morand D, Pereira B, Derost P, Ulla M, et al. Emergence of restless legs syndrome after subthalamic stimulation in Parkinson’s disease: a dopaminergic overstimulation? Sleep Med. 2015;16:583–8 Interesting discussion on the mechanism of RLS and its improvement by DBS.PubMedCrossRefGoogle Scholar
- 75.•Lettieri CJ, Eliasson AH. Pneumatic compression devices are an effective therapy for restless legs syndrome: a prospective, randomized, double-blinded, sham-controlled trial. Chest. 2009;135:74–80. The only randomized study on a non-drug therapy of idiopathic RLS.PubMedCrossRefPubMedCentralGoogle Scholar